drugset / Trial / NCT00601484

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00601484

Phase 2 Completed 65 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.

Timeline

Start
2008-03-17
Primary completion
2009-04-15
Completion
2009-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 200 ug/kg Intravenous

Indications